Page 232 - 2021_12-Haematologica-web

Case Report
CHU UCL Namur (OM070) was consulted to decide if reporting this case is ethically acceptable. This Ethical Committee (decision number: 27-21) was in favor of the publication of this case and did not see any ethical issue in publishing this case report. All data has been anonymized.
References
1. Morel-Kopp MC, Mullier F, Gkalea V, et al. Heparin-induced multi- electrode aggregometry method for heparin-induced thrombocy- topenia testing: communication from the SSC of the ISTH. J Thromb Haemost. 2016;14(12):2548-2552.
2. 2. Robert T. Proposed Brighton Collaboration process for developing a standard case definition for study of new clinical syndrome X, as applied to thrombosis with thrombocytopenia syndrome (TTS) - V10.16.3. Accessed on May 30, 2021. Available from: https://brightoncollaboration.us/wp- content/uploads/2021/04/TTS-Case-Finding-and-Definition- Process.v9.0-April-16-202115853.pdf.
3. 3. Guidance produced from the Expert Hematology Panel (EHP) focused on Covid-19 vaccine induced thrombosis and thrombocy- topenia (VITT) updated guidance on management. Version 1.3. Accessed on Apr 7, 2021. Available from: https://b-s- h.org.uk/media/19530/guidance-version-13-on-mngmt-of-throm- bosis-with-thrombocytopenia-occurring-after-c-19- vaccine_20210407.pdf.
4. Rosenberger LH, Smith PW, Sawyer RG, et al. Bilateral adrenal hem- orrhage: the unrecognized cause of hemodynamic collapse associat- ed with heparin-induced thrombocytopenia. Crit Care Med. 2011;39(4):833-838.
5. Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med.
2021;384(23):2202-2211.
6. BusselJB,ConnorsJ,CinesDB,etal.Thrombosiswiththrombocy-
topenia syndrome (also termed vaccine-induced thrombotic throm- bocytopenia). version 1.5. Accessed on Jul 26, 2021. Available from: https://www.hematology.org/covid-19/vaccine-induced-immune- thrombotic-thrombocytopenia.
7. Vayne C, Rollin J, Gruel Y, et al. PF4 Immunoassays in vaccine- induced thrombotic thrombocytopenia. N Engl J Med. 2021; 385(4):376-378.
8. PouplardC,LerouxD,RollinJ,etal.Incidenceofantibodiestopro- tamine sulfate/heparin complexes incardiac surgery patients and impact on platelet activation and clinical outcome. Thromb Haemost. 2013;109(6):1141-1147.
9. Nguyen T-H, Medvedev N, Delcea M, Greinacher A. Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoim- munity. Nat Commun. 2017;8:14945.
10.Platton S, Bartlett A, MacCallum P, et al. Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination. J Thromb Haemost. 2021;19(8):2007-2013.
11.Bourguignon A, Arnold DM, Warkentin TE, et al. Adjunct immune globulin for vaccine-induced thrombotic thrombocytopenia. N Engl J Med. 2021;385(8):720-728.
12.Rollin J, Pouplard C, Sung HC, et al. Increased risk of thrombosis in FcgammaRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2. Blood. 2015;125(15):2397-2404.
13.Warkentin TE. High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Expert Rev Hematol. 2019;12(8):685-698.
14. Svendsen PJ, Ward AM, Dati F, et al. New international reference preparation for proteins in human serum (RPPHS). Clin Chem. 1994;40(6):934-938.
15. Koleba T, Ensom MH. Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy. 2006; 26(6):813-827.
3252
haematologica | 2021; 106(12)